Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experience.
COVID-19
cancer pathways
cancer patients
chemotherapy
pandemic
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
06
2020
accepted:
13
08
2020
entrez:
24
9
2020
pubmed:
25
9
2020
medline:
25
9
2020
Statut:
epublish
Résumé
This study aims to compare the outcomes of COVID-19-positive disease in patients with a history of cancer to those without. We retrospectively collected clinical data and outcomes of COVID-19 positive cancer patients treated consecutively in five North London hospitals (cohort A). Outcomes recorded included time interval between most recent anti-cancer treatment and admission, severe outcome [a composite endpoint of intensive care unit (ITU) admission, ventilation and/or death] and mortality. Outcomes were compared with consecutively admitted COVID-19 positive patients, without a history of cancer (cohort B), treated at the primary centre during the same time period (1 March-30 April 2020). Patients were matched for age, gender and comorbidity. The median age in both cohorts was 74 years, with 67% male, and comprised of 30 patients with cancer, and 90 without (1:3 ratio). For cohort B, 579 patients without a history of cancer and consecutively admitted were screened from the primary London hospital, 105 were COVID-19 positive and 90 were matched and included. Excluding cancer, both cohorts had a median of two comorbidities. The odds ratio (OR) for mortality, comparing patients with cancer to those without, was 1.05 [95% confidence interval (CI) 0.4-2.5], and severe outcome (OR 0.89, 95% CI 0.4-2.0) suggesting no increased risk of death or a severe outcome in patients with cancer. Cancer patients who received systemic treatment within 28 days had an OR for mortality of 4.05 (95% CI 0.68-23.95), A diagnosis of cancer does not appear to increase the risk of death or a severe outcome in COVID-19 patients with cancer compared with those without cancer. If a second spike of virus strikes, rational decision making is required to ensure optimal cancer care.
Sections du résumé
BACKGROUND
BACKGROUND
This study aims to compare the outcomes of COVID-19-positive disease in patients with a history of cancer to those without.
METHODS
METHODS
We retrospectively collected clinical data and outcomes of COVID-19 positive cancer patients treated consecutively in five North London hospitals (cohort A). Outcomes recorded included time interval between most recent anti-cancer treatment and admission, severe outcome [a composite endpoint of intensive care unit (ITU) admission, ventilation and/or death] and mortality. Outcomes were compared with consecutively admitted COVID-19 positive patients, without a history of cancer (cohort B), treated at the primary centre during the same time period (1 March-30 April 2020). Patients were matched for age, gender and comorbidity.
RESULTS
RESULTS
The median age in both cohorts was 74 years, with 67% male, and comprised of 30 patients with cancer, and 90 without (1:3 ratio). For cohort B, 579 patients without a history of cancer and consecutively admitted were screened from the primary London hospital, 105 were COVID-19 positive and 90 were matched and included. Excluding cancer, both cohorts had a median of two comorbidities. The odds ratio (OR) for mortality, comparing patients with cancer to those without, was 1.05 [95% confidence interval (CI) 0.4-2.5], and severe outcome (OR 0.89, 95% CI 0.4-2.0) suggesting no increased risk of death or a severe outcome in patients with cancer. Cancer patients who received systemic treatment within 28 days had an OR for mortality of 4.05 (95% CI 0.68-23.95),
CONCLUSION
CONCLUSIONS
A diagnosis of cancer does not appear to increase the risk of death or a severe outcome in COVID-19 patients with cancer compared with those without cancer. If a second spike of virus strikes, rational decision making is required to ensure optimal cancer care.
Identifiants
pubmed: 32968429
doi: 10.1177/1758835920956803
pii: 10.1177_1758835920956803
pmc: PMC7493246
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835920956803Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
N Engl J Med. 2020 May 14;382(20):e61
pubmed: 32343498
Lancet. 2020 Mar 21;395(10228):e52
pubmed: 32171074
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622
Eur Heart J. 2020 Apr 07;:
pubmed: 32255475
Int J Infect Dis. 2020 Apr;93:297-299
pubmed: 32147538
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
Lancet Respir Med. 2020 May;8(5):430-432
pubmed: 32272081
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Lancet Oncol. 2020 May;21(5):629-630
pubmed: 32247319
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
JCO Glob Oncol. 2020 Apr;6:557-559
pubmed: 32250659
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143